An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein utilized by the immune system to identify and neutralize foreign objects such as bacteria and viruses . Antibodies are essential for the immune response, targeting specific antigens and triggering pathways that lead to the elimination of pathogens . Antibodies are heavy proteins of approximately 150 kDa in size, with a structure comprising three globular regions that form a Y shape . Each antibody unit in humans and most mammals consists of two identical heavy chains and two identical light chains, connected by disulfide bonds . Each chain contains a series of domains, which are sequences of about 110 amino acids each . Light chains have one variable domain (VL) and one constant domain (CL), while heavy chains have one variable domain (VH) and three to four constant domains (CH1, CH2, ...) .
Leronlimab is a humanized monoclonal antibody that targets the CCR5 receptor . CCR5, or C-C chemokine receptor type 5, is a protein found on the surface of certain immune cells, and it plays a role in the immune system by acting as a receptor for chemokines . Leronlimab has been used in the treatment of HIV-infected patients and has demonstrated minimal side effects in clinical use .
2.1. Leronlimab in Triple-Negative Breast Cancer (TNBC)
Leronlimab has shown potential in the treatment of triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer with limited treatment options . Research indicates that CCR5 is expressed in over 95% of TNBC samples, making it a relevant target for therapeutic intervention .
2.2. Effects of Leronlimab on Breast Cancer Cells
Studies have demonstrated that leronlimab binds to CCR5 in breast cancer cell lines, reducing ligand-induced calcium signaling, invasion into Matrigel, and transwell migration . Additionally, leronlimab enhances the effectiveness of chemotherapy reagents like doxorubicin in killing breast cancer cells . In xenograft models using mice, leronlimab significantly reduced lung metastasis of the TNBC cell line MB-MDA-231 .
2.3. Leronlimab Binding Efficiency
In experiments using MDA-MB-231 human breast cancer cells transfected with a human CCR5 expression vector, leronlimab showed high binding efficiency to CCR5-positive cells, reaching up to 98% .
LRRC52 antibody targets the N-terminal region of LRRC52, and has been tested for reactivity in humans . It is predicted to have homology to a variety of species including Human, Mouse, Rat, Cow, Dog, Guinea Pig, Horse, and Pig .
ANT1034 is a humanized monoclonal antibody that targets CD52 and has been developed to improve upon existing anti-CD52 therapies like alemtuzumab . Alemtuzumab, while effective in treating B cell malignancies, hematopoietic disorders, and autoimmune diseases, is associated with the development of anti-drug antibodies in a high proportion of patients . ANT1034 was engineered to reduce its potential for immunogenicity .
5.1. Superior Binding and Efficacy
ANT1034 exhibits superior binding to CD52-expressing cells compared to alemtuzumab . It is also more effective at directing both antibody-dependent and complement-dependent cell cytotoxicity . In preclinical studies, ANT1034 demonstrated greater efficacy in inducing apoptosis and improving survival in tumor xenograft models .
LCR52 (Low-molecular-weight Cysteine-Rich 52) belongs to a family of small cysteine-rich peptides in Arabidopsis thaliana that play various roles in plant development and stress responses. These peptides are characterized by their conserved cysteine residue patterns that contribute to their tertiary structure through disulfide bonding. The study of LCR52 using specific antibodies allows researchers to investigate signaling pathways, developmental processes, and plant defense mechanisms at the molecular level .
The LCR52 antibody has been validated specifically for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot applications. These techniques allow for both quantitative and qualitative analysis of LCR52 expression in plant tissues. The antibody enables researchers to detect native LCR52 protein in cellular extracts and can help identify protein-protein interactions when used in co-immunoprecipitation studies .
For optimal performance and longevity, LCR52 antibody should be stored at -20°C or -80°C immediately upon receipt. Repeated freeze-thaw cycles should be strictly avoided as they can lead to protein denaturation and loss of binding affinity. The antibody is supplied in a storage buffer containing 0.03% Proclin 300, 50% Glycerol, and 0.01M PBS at pH 7.4, which helps maintain stability. Working aliquots can be prepared to minimize freeze-thaw cycles for long-term projects .
Proper experimental controls are critical for interpreting results with LCR52 antibody. Researchers should include:
Positive control: Known LCR52-expressing tissues or recombinant LCR52 protein
Negative control: Tissues from LCR52 knockout plants or tissues known not to express LCR52
Secondary antibody-only control: To identify non-specific binding of the secondary detection system
Pre-absorption control: LCR52 antibody pre-incubated with excess recombinant LCR52 protein to confirm specificity
These controls help validate antibody specificity and distinguish true signals from background, similar to validation approaches used with other research antibodies .
For Western blot analysis with LCR52 antibody, researchers should follow this methodological approach:
Sample preparation: Extract proteins from plant tissues using a buffer containing protease inhibitors
Protein separation: Use 15-18% SDS-PAGE gels due to the small size of LCR52 protein
Transfer: Employ PVDF membranes (0.2 μm pore size) with a semi-dry transfer system
Blocking: 5% non-fat milk in TBST for 1 hour at room temperature
Primary antibody: Dilute LCR52 antibody 1:1000 in blocking buffer and incubate overnight at 4°C
Washing: 3-5 washes with TBST, 5 minutes each
Secondary antibody: Anti-rabbit HRP-conjugated, 1:5000 in blocking buffer for 1 hour
Detection: Use enhanced chemiluminescence for visualization
This protocol can be optimized based on specific experimental requirements and tissue types .
LCR52 antibody works effectively with:
Whole plant tissue extracts: Fresh tissues homogenized in extraction buffer
Cell suspension cultures: Pelleted cells lysed with appropriate buffer
Subcellular fractions: Isolated using differential centrifugation techniques
Recombinant expression systems: E. coli or insect cell-derived recombinant proteins
Sample preparation should include protease inhibitors to prevent degradation of the target protein. For plant tissues with high levels of interfering compounds, additional purification steps such as acetone precipitation or TCA/acetone extraction may improve results .
For subcellular localization of LCR52 protein:
Tissue fixation: Use 4% paraformaldehyde for 2-4 hours
Sectioning: Prepare 5-10 μm sections using a microtome
Antigen retrieval: Citrate buffer (pH 6.0) treatment may enhance signal
Blocking: 5% BSA or normal goat serum in PBS for 1 hour
Primary antibody: LCR52 antibody diluted 1:200, incubate overnight at 4°C
Secondary antibody: Fluorophore-conjugated anti-rabbit IgG
Counterstaining: DAPI for nuclear visualization
Mounting: Anti-fade mounting medium
Imaging: Confocal microscopy with appropriate filters
This methodology enables visualization of LCR52 distribution within plant cells and tissues, which can provide insights into its functional roles .
While not specifically validated for ChIP applications, researchers interested in exploring transcriptional regulation could attempt LCR52 antibody adaptation for ChIP with these methodological considerations:
Crosslinking: Use 1% formaldehyde for protein-DNA crosslinking
Chromatin shearing: Sonicate to generate 200-500 bp fragments
Pre-clearing: Incubate chromatin with protein A/G beads and non-immune IgG
Immunoprecipitation: Use 5-10 μg LCR52 antibody per sample
Washing: Stringent wash buffers to reduce background
Elution and crosslink reversal: 65°C incubation for several hours
DNA purification: Standard phenol-chloroform extraction
Analysis: qPCR or next-generation sequencing
Since this application extends beyond validated uses, extensive optimization and controls would be necessary to establish reliability .
Common issues and their solutions include:
| Issue | Potential Cause | Solution |
|---|---|---|
| False positives | Cross-reactivity with related proteins | Pre-absorb antibody with recombinant related proteins |
| Non-specific binding | Optimize blocking, increase washing stringency | |
| Secondary antibody issues | Include secondary-only control | |
| False negatives | Protein degradation | Use fresh samples, add protease inhibitors |
| Epitope masking | Try different extraction buffers, consider antigen retrieval | |
| Insufficient antibody | Increase antibody concentration | |
| Inefficient transfer (WB) | Optimize transfer conditions for small proteins |
Careful optimization of experimental conditions and inclusion of appropriate controls can significantly reduce these issues .
Multiple validation approaches should be employed:
Genetic validation: Compare results from wild-type and LCR52 knockout/knockdown lines
Molecular weight confirmation: Ensure detected bands match predicted size of LCR52
Peptide competition: Pre-incubate antibody with excess immunizing peptide to block specific binding
Orthogonal methods: Confirm findings using independent techniques (e.g., mass spectrometry)
Recombinant expression: Test antibody against overexpressed LCR52 with epitope tags
Multiple antibody approach: When available, compare results with other LCR52 antibodies
This multi-faceted approach significantly increases confidence in antibody specificity and research findings .
The LCR52 antibody was raised against Arabidopsis thaliana LCR52 and is specifically validated for this species. Cross-reactivity with homologous proteins in closely related species may occur but requires empirical validation. Potential cross-reactivity depends on sequence conservation in the epitope region. Researchers working with other plant species should:
Perform sequence alignments to identify conservation with A. thaliana LCR52
Run pilot experiments with appropriate controls
Consider pre-absorption tests with heterologous proteins
Validate any cross-reactivity findings with additional techniques
Sequence homology analysis can provide preliminary expectations, but experimental verification remains essential .
Different detection methods offer varying advantages when working with LCR52 antibody:
| Method | Sensitivity | Quantification | Spatial Information | Sample Requirements |
|---|---|---|---|---|
| Western Blot | Moderate | Semi-quantitative | None | Denatured proteins |
| ELISA | High | Quantitative | None | Native or denatured |
| Immunohistochemistry | Moderate | Semi-quantitative | Tissue/cellular | Fixed tissue sections |
| Immunofluorescence | High | Semi-quantitative | Subcellular | Fixed cells/tissues |
| Flow Cytometry | High | Quantitative | None | Single cell suspensions |
Selection of the appropriate method depends on research objectives. ELISA provides the most quantitative data, while imaging techniques offer valuable spatial information .
For rigorous quantitative analysis:
Western blot densitometry:
Use technical replicates (3-4 minimum)
Include loading controls (actin, tubulin, or total protein stains)
Employ gradient standards for calibration
Utilize specialized software (ImageJ, Image Lab) for band quantification
Apply statistical analysis to determine significance
ELISA quantification:
Generate standard curves using recombinant LCR52
Ensure samples fall within the linear range
Use multiple dilutions of each sample
Include intra-plate controls for normalization
Calculate concentration based on standard curve regression
Complex experimental designs require careful planning and analysis:
Temporal considerations:
Establish appropriate time points based on known plant developmental stages
Include sufficient sampling frequency to capture dynamic changes
Consider diurnal variations in expression
Spatial considerations:
Analyze tissue-specific expression patterns
Compare different organs or cell types
Consider developmental gradients within tissues
Environmental variables:
Maintain strict control of growth conditions
Document all variables that might influence results
Design experiments with appropriate controls for each stress condition
Data integration:
Correlate protein data with transcriptomic analyses
Consider post-translational modifications
Evaluate protein-protein interactions through co-immunoprecipitation
This comprehensive approach provides context for interpreting LCR52 function in complex biological systems .
Emerging microscopy approaches offer new possibilities:
Super-resolution microscopy:
Techniques like STED, PALM, or STORM can resolve LCR52 localization beyond the diffraction limit
Enables visualization of protein clusters and microdomains
Requires fluorophore-conjugated secondary antibodies with appropriate photophysical properties
Live-cell imaging adaptations:
While direct antibody use requires cell fixation, findings can inform the design of fluorescent protein fusions
Correlative approaches combining LCR52 immunolabeling with live-cell imaging provide temporal context
Multiplexed imaging:
Simultaneous detection of LCR52 with interaction partners
Requires careful selection of compatible fluorophores and image acquisition parameters
These advanced techniques can provide unprecedented insights into LCR52 dynamics and interactions at the subcellular level .
For investigating LCR52 protein interactions:
Co-immunoprecipitation (Co-IP):
Use crosslinking agents to stabilize transient interactions
Optimize extraction buffers to maintain complex integrity
Consider native vs. denaturing elution conditions
Verify results with reciprocal Co-IP using antibodies against putative interaction partners
Proximity ligation assay (PLA):
Enables in situ detection of protein interactions
Requires antibodies from different host species against LCR52 and putative partners
Provides spatial information about interaction events
Allows quantification of interaction frequency
Pull-down assays:
Use recombinant LCR52 as bait for identifying novel interactions
Validate findings with Co-IP using LCR52 antibody
These methodologies can reveal the functional interactome of LCR52, providing insights into its biological roles .